Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
ArcelorMittal (MT) trades near $70.81 after a year of operational improvements, capital returns and a clear decarbonization plan. New and prospective import controls on steel in North America and elsewhere are a direct demand/price tailwind for integrated steelmakers. Combine policy support with a $53.9B market cap, €1.3bn investment in an electric…
Nebius is executing a rapid data-center expansion to capture AI compute demand. With Q1 revenue growth of 684% and a $46 billion contracted backlog, the stock offers asymmetric upside if execution holds. This swing trade buys into that growth while setting a clear stop in case expansion problems or funding pressure reappear.
CAVA Group (CAVA) looks actionable on a technical pullback or at-the-market entry. The stock is trading above the 50-day and 21-day EMAs, the MACD histogram is positive, and RSI is bullish but not extreme. Fundamentals show accelerating revenue and same-restaurant sales strength, while valuation remains stretched. This trade balances momentum with …
Applied Optoelectronics (AAOI) has become a go-to supplier for optical transceivers and laser diodes as hyperscalers and AI data-center builders accelerate connectivity spending. The stock has already rallied dramatically, but balance-sheet strength, tight short interest and clear demand catalysts make a tactical long attractive from current levels…
AppLovin (APP) is trading like a growth software name with monster profitability. Strong Q1 prints and the roll-out of Axon AI have pushed revenue and margins higher; the market is pricing a premium (P/E ~42, P/S ~27). This trade idea outlines a disciplined long with entry at $497.00, stop at $430.00 and a $650.00 target over a 180 trading-day hori…
Electromed (ELMD) is a compact medical-specialties company punching above its weight: roughly $72M of implied revenue, double-digit free cash flow margins, zero debt and solid returns on capital. Technicals are constructive and the stock trades below a recent $40 52-week high. We outline a long trade with a $37.00 entry, $33.00 stop and $45.00 targ…
RH (Restoration Hardware) is a high-end furniture and home-lifestyle name trading well below prior highs despite solid free cash flow, expanding international presence, and continued pricing power. At roughly $153, shares offer asymmetric upside to $220 over a multi-month horizon while offering an attractive free cash flow yield; downside is real, …
Memory chip prices have spiked more than sixfold in the past year, a shift Morgan Stanley analysts describe as structural. Forecasts cited in the analysts' note project the memory market to expand from roughly $220 billion in 2025 to about $890 billion in 2026, driven primarily by price increases tied to surging demand for AI-focused memory such as…
Micron sits at the center of an AI-driven memory squeeze. At roughly $990 today, the stock is expensive by some multiples, but the company's cash generation, low leverage and the prospect of sustained DRAM/NAND pricing make a long position attractive. This trade plan lays out exact entry, stop and target levels across a 180-trading-day horizon and …
Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…
Nabors is showing signs of an earnings inflection backed by improving rig demand and operational wins. The stock is cheap on P/E and EV/EBITDA while technicals show constructive momentum. This trade idea lays out a mid-term (45 trading days) long with entry, target, and stop-loss, plus catalysts and risks that would change the view.
Protagonist (PTGX) is trading like a pure clinical biotech despite meaningful de-risking: a partner-approved oral IL-23R pill (Icotyde) that just delivered a $50M milestone and an NDA for rusfertide in polycythemia vera moving toward potential approval. The shares have momentum, a $7.06B market cap and limited debt, creating a tradeable long with d…
Analysts at Bernstein conclude that multiple hardware approaches - including superconducting, trapped-ion and neutral-atom systems - all retain competitive advantages, making a single dominant vendor unlikely. Bernstein expects meaningful commercial quantum advantage around 2030, sizes the long-term addressable market at $90 billion to $170 billion…
Broadcom's guidance note that gross profit margins will continue to fall is a clear structural headwind for a stock trading at premium multiples. Fundamentals still look strong, but the market is paying a very high price for near-term margin stability. This trade idea proposes a short-swing (45 trading days) position sized to the risk, with explici…
Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…
Bank of America analysts caution that a prospective U.S.-Iran agreement, while removing a geopolitical premium, could leave crude oil in a price band that increases inflationary pressure just enough to deter Federal Reserve rate cuts and potentially lead to further tightening instead of relief markets recently priced in.
Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …
Nano Labs (NA) is a small, China-based fabless semiconductor firm with high-performance computing chips, smart NICs and distributed storage products. The stock trades at a $41M market cap, P/E ~1.85 and P/B ~0.38, while recent partnerships and product rollouts give the company optionality into North American AI data centers. This is a high-risk, ta…
Zhihu trades at a sub-$300M market cap with a price-to-book under 0.5 and signs of recent operational improvement. Elevated short interest and AI-driven threats make this a volatile trade, but the combination of non-GAAP profitability quarters, margin expansion commentary, and board refreshes argue for a tactical long with tight risk controls.
Sea (SE) has a Shopee profitability problem that is visible in short-term margin squeezes. But the company’s balance sheet, record adjusted EBITDA, and accelerated revenue growth give multiple levers to restore profitability and drive re-rating. This trade idea lays out specific entry, stop, and target levels tied to a 180 trading-day thesis.
G Mining Ventures is being priced like a steady-state miner despite being in the mine-builder phase. If management hits near-term permitting and financing milestones, the stock should re-rate. This trade targets a meaningful upside while protecting capital if the developer stalls.
Range Resources (RRC) looks attractively priced at $38.58 with last reported free cash flow near $878M and a low debt load. Strong realized energy prices and recent dividend increases support a thesis that Range can generate roughly $800M of free cash flow in 2026, underpinning earnings, buybacks and a higher dividend. The trade: enter $38.58, targ…
Capital One has retraced roughly 27% from its January highs, trading near $185 and offering an attractive risk-reward for a tactical long. The Discover acquisition and targeted $2.7B of synergies, improving auto loan performance, strong free cash flow, and a modest balance sheet give the company room to reclaim lost ground. I recommend a mid-term s…
SpaceX's recent U.S. IPO lifted its market value past $2 trillion and placed it ahead of two firms long included among Wall Street's 'Magnificent Seven.' The listing has prompted market participants to question whether the Mag 7 shorthand still captures the leading cohort of mega-cap tech companies, spurring proposals for new acronyms that would in…
Texas has shifted from a safe Republican hold to a competitive battleground after Attorney General Ken Paxton upset four-term Senator John Cornyn in a runoff following a late endorsement from former President Donald Trump. Paxton faces Democratic state Representative James Talarico, who has significantly outpaced him in fundraising. Republican stra…
